NCI SBIR Announces $8 Million in New Contract Funding Opportunities for Innovative Small Businesses in Cancer Research and Technology Development
Is your small business on the brink of taking its innovative cancer research to the next level, but needs early-stage technology financing? If so, we encourage you to apply for new contract funding opportunities available from the National Cancer Institute’s (NCI) Small Business Innovation Research (SBIR) Program by November 7, 2011.
The NCI SBIR Program is publishing contract topics that represent technology areas that both meet the scientific priorities of the NCI and are ripe for commercial investment and integration. The solicitation of contract proposals in these topic areas are intended to help finance and lead innovations in cancer prevention, detection, diagnosis, treatment, and basic research. Contract funding opportunities are only available once a year, SO APPLY EARLY!!!
This year, the NCI SBIR Program has released $8 million for 12 new contract funding opportunities in a range of novel technology areas. Compared to grant funding opportunities, SBIR contract topics focus on scope and require the completion of specific activities and deliverables. The current NCI FY2012 solicitation provides funding opportunities to small businesses to support the research, development, and commercialization of many areas of priority to the NCI including, but not limited to:
|
|
In addition, the NCI SBIR Program has also announced three NIH Technology Transfer (TT) Inventions released as contract topics. The goal of each SBIR-TT topic is to identify a small business which can obtain both SBIR funding and licenses to the technology to perform the necessary R&D to advance the technology towards commercialization.
The FY2012 technology transfer contract topics are:
- 310 Simplified Tumor Microarray Instrument for Clinical and Research Settings
- 311 High Throughput Isolation of Antigen Specific T-cells for Cancer Therapy
- 075 A Low Molecular Weight Thyroid-Stimulating Hormone Receptor Agonist for Thyroid Cancer – Funding will be provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), while the receipt, review, and contracting will be handled by NCI.
Learn more about NCI’s SBIR Programs and these contract funding opportunities.
NCI SBIR Program Participation:
To participate, the small business concern (SBC) must be an organized for-profit U.S. business of 500 employees or fewer, including affiliates.
The SBC must:
|
Funding Benefits:
- SBIR & STTR awards provide recognition, verification, and visibility;
- SBIR & STTR funding can be a leveraging tool to attract additional funding from other third-party investors; and,
- Awards are not loans; no repayment is required
SBIR & STTR funding is non-dilutive capital (i.e., an award does not impact the company’s stock or shares in any way). Intellectual property rights to technologies developed under these programs are retained by the small business concern.
View a complete listing of all funding opportunities available.
The SBIR & STTR Programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. The SBIR & STTR Programs are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.
Sign up to receive updates about
SBIR & STTR funding opportunities at
sbir.cancer.gov
